

## PMP - Comments on CLH report


### 10. Health hazards -Read-across justification

We agree that the classification proposal should only be based on the data on phenmedipham itself, but not with the proposal that this should be supported by read-across from desmedipham and their assumed common metabolites. We disagree with the statement that the chemical structure, chemical properties, breakdown products and toxicological profiles of desmedipham and phenmedipham are similar since it is known that even within the same compound classes between compounds with similar structures differences in their toxicological profiles can occur. From the metabolic pathways shown in the table under this chapter it is obvious that the metabolic pathways show differences so that this does not support the stated similarity of both molecules. Some of the endpoints appear to be similar, like the hematological effects, however, depending from the study type and species, the potency and reference doses are different.


#### Aniline formation

In the CLH report based on read-across it is stated that formation of aniline may happen in the metabolism of phenmedipham, like it is suggested for desmedipham. However, the statement that in the metabolism of desmedipham as one of the metabolites aniline may happen was not confirmed in the ADME studies since aniline was not detected in them. This is also unlikely as stated in the CLH report for desmedipham due to the fact “that in the metabolic pathway of desmedipham, the first metabolite of the PC ring radiolabelled form was PMC (phenyl methyl carbamate), which was supposed to convert to aniline and then further rapidly to 4-aminophenol and at last acetylated to 4-acetaminophenol. However, aniline was not detected in metabolism studies in rat.” Based on the quick conversion to 4-aminophenol apparently no aniline is occurring at measurable amounts if at all which is demonstrated by the fact that no aniline was detected in the ADME studies with desmedipham.

It is stated in the CLH report that “There are slight differences in the substances formed during metabolism between the two substances. The first step of metabolism pathways seems to be slightly different. The –NHCOO– group in between the aromatic rings is metabolised in the first step to –NH<sub>2</sub> and HO– in phenmedipham and to –NHCOOCH<sub>3</sub> and HO– for desmedipham. However, both substances are suggested to produce compounds which have aromatic amine structure. Some of the identified metabolites are common for both substances such as 3-aminophenol and various acetamidophenols. Phenmedipham is also suggested to produce acetamidocarboxylic and salicylic acids, which are not identified in the toxicokinetic studies of desmedipham. Not detected in the studies but phenmedipham is also suggested to produce aniline.” Like we disagree with the statement that aniline occurs as metabolite of desmedipham as explained before, **we especially disagree with the speculation that phenmedipham could produce aniline.** This is impossible based on the structure of phenmedipham and since it was not demonstrated for desmedipham this speculation can even not be supported by read-across from desmedipham. This is confirmed by our experts with their statement “ There is no indication that aniline is formed from phenmedipham. The corresponding counterpart of methyl 3-hydroxyphenylcarbamate (MHPC), which was detected as a major plant metabolite, is m-toluidine (3-methylaniline) and not aniline. M-toluidine was not detected in the ADME nor in livestock metabolism studies, however 4-amino-o-cresol and other possible subsequent metabolites (3-methylacetanilide, 3-aminobenzoic acid) - therefore m-toluidine was proposed as an intermediate metabolite (see structures below).



m-toluidine



4-amino-o-cresol

The formation of aniline from all these metabolites is not reasonable.”

Thus, we conclude that neither from desmedipham nor from phenmedipham production of aniline in the metabolic pathway is evident.

### Genotoxicity

In the table “Toxicology comparison of desmedipham and phenmedipham” under genotoxicity it states “Negative Ames, Negative OECD 476, Positive OECD 473 (2), OECD 474 (+/-), negative OECD 483 (exposure not shown)”. We agree with the statement that “phenmedipham is not genotoxic in vivo.”, but the statement in the table that “exposure is not shown” is not correct since in a special study bone marrow exposure was demonstrated as also acknowledged later in the CLH report. Results of a special study on bone marrow exposure are available. Bone marrow exposure was clearly demonstrated in a mouse quantitative whole body autoradiography study (██████████). Thus, the available data provide evidence for the presence of the test substance systemically and in the bone marrow. Furthermore, test substance was detected systemically and in the bone marrow in toxicokinetic studies: In an ADME study (██████████), mean plasma levels of methylphenyl-labelled phenmedipham, which were measured 96 hours after administration of a single dose of 1000 mg/kg bw, were 23.6 and 41.0 µg/g in males and females, respectively. Maximum individual levels of up to 68.9 µg/g were reached in females. In bone marrow, mean levels of 1.65 and 2.24 µg/g were measured in males and females, respectively, with maximum individual levels of up to 4.8 µg/g in females. In addition, toxicity to the bone marrow was shown in the micronucleus test: The guidance states that a decrease in the ratio of polychromatic to normochromatic erythrocytes is sufficient evidence of bone marrow exposure. In one of the micronucleus studies (██████████, 1985), phenmedipham was tested at an oral gavage dose of 15,000 mg/kg bw (>7X the currently recommended limit dose). This dose caused a reduced polychromatic erythrocyte count (PCE) which, according to the study director, was evidence that the dose affected erythropoiesis. There was no effect of treatment on micronucleus induction in this study.

These data support the line of evidence that the bone marrow was exposed sufficiently at this high dose level in the micronucleus test as was also stated by the external genotoxicity expert, ██████████ (see Appendix 1) :

“Collectively, the above lines of evidence clearly indicate that bone marrow was exposed to the test substance in the mouse micronucleus tests on phenmedipham. Since phenmedipham was tested up to a dose level of 15,000 m/kg bw (more than 7X the limit dose for these studies), it is reasonable to conclude that the substance was tested at high enough doses to result in sufficient exposure of bone marrow. The available data to support bone marrow exposure in phenmedipham micronucleus studies are rather exemplary.”

We do not agree to the statement that no ‘exposure was shown’ for the test according to OECD483 in the table “Toxicology comparison of desmedipham and phenmedipham”. It is concluded that in the dominant lethal assay in which phenmedipham did not cause chromosomal aberrations, sufficient exposure of the spermatogonia to phenmedipham must have occurred. Based on ADME study results the compound concentrations in testes were 3.0 µg/g tissue which is corresponding to 0.004% of dose as measured 96 hours after administration of 1,000 mg/kg bw of methylphenyl labelled phenmedipham. Since in this study a dose of 15,000 mg/kg bw was administered a much higher concentration in the

testes tissues than 3.0 µg/g can be expected. Therefore a sufficiently high exposure can be assumed for this extremely high dose so that the validity of this test is supported by the exposure data.

Based on the above information, also the presentation of the OECD 474 results for phenmedipham as +/- is not correct. The tests were negative and exposure has been shown.

Overall, we agree to the CLH conclusion that there is no evidence of a genotoxic potential which would warrant classification.

**Under 10.10.1 Carcinogenicity the CLH report states: Increased incidences of neoplasms in phenmedipham treated rats were observed in two studies. The incidence of endometrial stromal sarcoma was increased at 34 mg/kg bw/day (6% vs. 2% in controls, historical control range of the performing laboratory 0-4%) in the study by ██████████ B.6.5.1/06 M-145589-01-1. In the study (2004 M-240148-01-1 B.6.5.1/07), the incidence of adenomas in the pars distalis of the pituitary in male Wistar rats showed a dose-dependent increase that was found to be statistically significant (time-to-tumour method) at 118 mg/kg bw/day (38% vs. 14% in controls, all animals).**

We disagree with the proposed carcinogenicity cat. 2 classification due to the endometrial stromal sarcoma incidences. The incidences for this finding in the Reno, 1980 study in SD rats are shown in the following table:

Overview on endometrial stromal sarcoma incidences

104-week necropsy	Females				HCD <sup>a</sup>	HCD <sup>b</sup>	HCD <sup>c</sup>
Dose (ppm)	0	20	100	500			
N=	50	50	49	50			
Uterine findings							
Endometrial stromal sarcoma:	1	0	2	3	12/2275		
Incidence %	2.0	0	4.1	6.0	0-4.0	0-6	0-18

<sup>a</sup> Historical control data from Covance (formerly Hazleton, ██████████) (104-week studies in SD rats between 1980 and 1990)

<sup>b</sup> Historical control data from ██████████, 1994

<sup>c</sup> Historical control data from a catalogue from Charles River with HCD of Sprague-Dawley rats from studies between 1994 and 1996

It can be seen that the incidence in the control group with 2 % is rather at the higher end of the HCD range so that apparently this batch of animals had a higher background incidence of this finding. This puts the incidence at the highest dose in perspective as this is likely probably not above the HCD of this animal batch. A publication about HCD of endometrial stromal sarcoma incidences in Wistar rats at that time period gives a HCD range of 0-6 % (██████████). In a catalogue from ██████████ with HCD of Sprague-Dawley rats from studies between 1994 and 1996 incidences of a maximum of 18 % is given. The published ranges show that the normal variability range in rats of the same and of a different rat strain is higher than the limited HCD in the report. Thus, it seems that in general this finding has a higher background incidence than the limited HCD set given in the report, so that the incidences in the study are regarded as covered by the available HCD data.

Most importantly, a trend test (Exact Cochran-Armitage test from SAS test) which was performed with the incidences in this study (see table above) did not prove a positive trend. This is a very powerful test to check incidences on a dose-related trend and much better than others, like chi-squared test.

The report states:

“The Exact One-sided (increasing linear trend, indicated by a low p-value) and two-sided (increasing or decreasing linear trend, indicated by a low p-value) Cochran-Armitage Trend Tests are displayed.

One-sided Pr  $\leq Z$  0.0693

Two-sided Pr  $\geq |Z|$  0.1220

The two results from the Exact Test lead us to conclude, that there is no trend associated with the results, i.e. the probability of incidence='Yes' doesn't increase with larger doses. "

Thus no evidence of a dose-related treatment effect exists so that this test proves a lack of a treatment effect on these tumor incidences.

### Incidence of adenomas in the pars distalis of the pituitary in male Wistar rats

We disagree with the statement in the CLH report that the incidence of adenomas in the pars distalis of the pituitary in male Wistar rats in the long-term rat study from [REDACTED] (M-240148-01-1) is regarded as dose-related.

An overview of the incidences of adenomas in the pars distalis of the pituitary, including HCD is given in the following table:

Pituitary, pars distalis	Dose (ppm)				Historical data 1995-2006 (%)
	0	100	500	2500	
<b>Males</b>					
Adenoma (%)	14	14	24	38	12.0 – 45.0
Adenocarcinoma (%)	0	0	0	0	0.0 – 1.9
Focal hyperplasia (%)	12	16	6	16	na
<b>Females</b>					
Adenoma (%)	46	66	52	52	45.0 – 76.7
Adenocarcinoma (%)	6	0	2	4	0.0 – 12.0
Focal hyperplasia (%)	28	20	20	10	na

Na not available

It can be seen that no increased tumor incidence of pituitary adenomas is seen in females and only a slight and spurious increase of the incidences in males. These findings are due to variability and not to treatment. Especially the fact that the incidence of these tumors was not affected in females speaks against a treatment relationship. It is more likely that the incidences are due to a high variability of this finding which is known from other strains, too. This is especially seen in the HCD which were provided from the same laboratory which conducted the study and which demonstrate a high variability of this finding in males between the studies from 12 to 45 % in males and of 45 to 76.7 % in females, despite the fact that all parameters (strain, diet, husbandry etc.) were the same. Also no dose-related increase in the incidence of precursors, like focal hyperplasia or of adenocarcinoma incidences of the part distalis was seen which however would be expected in case of a treatment relationship. Also the fact that the total incidence of benign and malignant tumors was not increased speaks against a treatment relationship, see following overview:

	Incidences							
	Males				Females			
	0	100	500	2500	0	100	500	2500
Dose (ppm)	0	100	500	2500	0	100	500	2500
No. of animals	50	50	50	50	50	50	50	50
No. of animals with tumors	31	33	36	35	40	43	42	41
No. of animals with single tumors	17	22	21	24	20	20	22	25
No. of animals with multiple tumors	14	11	15	11	20	23	20	16
No. of animals with benign tumors	30	29	34	35	35	47	41	41
No. of animals with malignant tumors	7	3	5	2	10	7	12	10
No. of animals with metastasising tumors	1	2	2	1	4	3	5	8

Total number of tumors	51	50	56	51	65	78	66	63
Total number of benign tumors	44	47	50	48	53	68	54	53
Total number of malignant tumors	7	3	6	3	12	10	12	10
Total number of metastasising tumors	1	2	1	1	4	4	5	8
% Animals with tumors	62	66	72	70	80	86	84	82
% Animals with single tumors	34	44	42	48	40	40	44	50
% Animals with multiple tumors	28	22	30	22	40	46	40	32
% Animals with benign tumors	60	58	68	70	70	94	82	82
% Animals with malignant tumors	14	6	10	4	20	14	24	20
% Animals with metastasising tumors	2	4	4	2	8	6	10	16

We disagree with the statement in the CLH report that “although no definite conclusion can be drawn it is plausible that the occurrence of these tumours is hormonally related, namely by disturbed homeostasis of the hypothalamus-pituitary-gonad (thyroid) axis”.

The alleged hormonal association of the aforementioned tumors is not supported by the toxicology data for phenmedipham, since based on the toxicology studies with PMP there is no evidence of an endocrine potential. The cited effects on some hormone sensitive organs (e.g. decreases in uterus, prostate and thymus weights and increases in adrenals, testes and ovaries weights in rats) do not support a hormonal relationship due to treatment since they were mostly not dose-related and/or secondary to body weight effects or toxicity and a hormonal impact on such different organs from different sexes and thus different hormonal mechanisms appears rather implausible. This is discussed as follows.

### **Testicular findings**

It is stated that the reduced incidences of testicular seminiferous tubular atrophy, of spermatozoa absent degenerate spermatogenic cells in ducts could be associated with the changed incidence of pituitary adenomas. However, the incidences of pituitary adenomas are not regarded as affected by treatment so that a relationship is unlikely. The incidences of the aforementioned non-neoplastic findings were not increased but decreased so that a direct effect of the treatment can be excluded, especially since no other effects in the testes or in the epididymides, especially no negative effects or damages were seen. Also no such findings occurred in the interim sacrifice after 52 week which would be expected if they were directly associated with the treatment. Furthermore, no similar findings occurred in the other long-term studies.

### **Mammary acinar hyperplasia**

Also the association between the reduced incidences of the mammary acinar hyperplasia with the changed incidence of pituitary adenomas is not obvious. The incidences of this finding with 13/30, 8/38, 11/35 and 5/31 for controls and the doses 100, 500 and 2500 ppm, respectively do not show a clear dose- and thus treatment-related effect. Also other findings in the mammary gland which would indicate a negative effect on this organ were not seen and especially negative effects, like increased tumor incidences did not occur. Also in other studies no mammary gland findings indicating a negative impact were noted.

### **Organ weights of endocrine organs in short-term studies**

The DRAR, 2016 suggests that some weights of endocrine organs appear to be changed and thus indicate some endocrine effects in some of the phenmedipham studies. In the following text it is analyzed whether such organs are affected in a dose-related manner in the different studies with phenmedipham.

### Pituitary weight:

In a subchronic rat study (████████ 1986b, M-145380-02-1) with doses of 0, 150, 500 and 1500 ppm, the slightly decreased pituitary weights in males only (do not show a distinct dose response, the decreased relative pituitary weight at the highest dose is due to a higher body weight in this group as compared to the controls. The following tables give an overview of the pituitary weights of males in subchronic and chronic studies:

#### Subchronic studies

Study	Pituitary weight (males)	Doses (ppm)											
		0	50	150	400	500	800	1000 <sup>a</sup> / 1200	1500	3000	5000	10000	20000
Subchronic studies													
████████, M-146380-02-1 (SD)	absol (g)	0.013		0.013		0.011			0.010**				
	rel (%)	0.00276		0.00265		0.00231*			0.00203***				
████████, M-146355-02-1 (SD)	absol (g)	0.0116			0.0107		0.0116	0.0121					
	rel (%)	0.0022			0.0021		0.0023	0.0024					
████████, M-145614-01-1 (F344)	absol (g)	0.008	0.009			0.007					0.008		
	rel (%)	0.003	0.003			0.002					0.003		
████████ 2002 M-211096-01-1 (Wistar rats) <sup>b</sup>	absol (g)	0.009						0.009		0.008		0.006*	0.005***
	rel (%)	0.0017						0.0019		0.0017		0.0016	0.0013

(SD) = Sprague-Dawley rats

F344 = Fischer 344 rats

<sup>a</sup> 1000 ppm in study of Foulon, 2002

<sup>b</sup> Absolute weight reductions due to very high body weight reductions at  $\geq 3000$  ppm

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$

#### Chronic studies

Study	Pituitary weight (males)	Doses (ppm)			
		0	60	250	1000
Chronic studies					
████████, 1980 M-145589-01-1 (SD)	absol (g) week 52	0.0104	0.0102	0.0100	0.0116
	rel (%) week 52	0.0019	0.0017	0.0017	0.0020
	absol (g) week 104	0.0837	0.0445	0.0386	0.0524
	rel (%) week 104	0.0181	0.0082	0.0070	0.0111

This overview demonstrates that in other subchronic toxicity studies with similar doses and also in a long-term study no effects on the pituitary weights were observed. The slightly decreased pituitary weights in the ██████████ 2002 study were caused by severe body weight effects of the very high doses used

in this study as can be seen in the relative weights which did not show such an effect. If it would be assumed that phenmedipham would have such an effect, this should be especially seen in the long-term studies with longer exposure duration, however, this was not the case. Thus, overall from the apical studies, no evidence of an effect on the pituitary weight was obvious. Therefore it is concluded that this pituitary weight change was a spurious chance finding due to variability.

### Uterus weight:

In a subchronic rat study (██████, 1986a, M-146355-02-1) with doses of 0, 400, 800 and 1200 ppm, the uterus weight reduction is regarded as a spurious chance effect due to high variability and the very high control weight, as compared with uterus weights from other subchronic rat studies. Most importantly, in other subchronic toxicity studies with similar or even higher doses no effects on the uterus weights occurred (██████ 1986b, M-146380-02-1; ██████ 2002, M-211096-01-1). Therefore this was a spurious chance finding due to variability.

An overview of the uterus weights in different studies is given in the following tables:

#### Subchronic studies

Study	Uterus weight	Doses (ppm)										
		0	150	400	500	800	1000	1200	1500	3000	10000	20000
Subchronic studies												
██████, 1986a, M-146355-02-1 (SD)	absol (g)	0.820		0.661		0.563*		0.606*				
	rel (%)	0.309		0.245*		0.212*		0.238*				
██████, 1986b, M-146380-02-1 (SD)	absol (g)	0.69	0.87		0.68				0.77			
	rel (%)	0.24	0.32		0.24				0.28			
██████, 2002 M-211096-01-1 (Wistar rats) <sup>a</sup>	absol (g)	0.584					0.808			0.533	0.398**	0.393*
	rel (%)	0.224					0.312			0.215	0.184	0.186

(SD) = Sprague-Dawley rats

a Absolute weight reductions due to very high body weight reductions at  $\geq 3000$  ppm

\*  $p < 0.05$ , \*\*  $p < 0.001$

#### Chronic studies

Study	Uterus weight	Doses (ppm)			
		0	100	500	2500
Chronic/ carcinogenicity study					
██████, 2004, M-240148-01-1 (HanWistar)	absol (g) week 52	0.848	0.664	0.777	0.915
	rel (%) week 52	0.3271	0.2630	0.2864	0.3794
	absol (g) week 104	0.797	0.651	0.854	0.760
	rel (%) week 104	0.2382	0.1938	0.2587	0.2764

It is obvious from the overview that the other studies do not confirm any treatment-related effect on the uterus weights. The slightly decreased uterus weights in the ██████, 2002 study were caused by severe

body weight effects of the very high doses used in this study as can be seen in the relative weights which did not show such an effect. If phenmedipham would have an effect, this should be especially seen in the long-term studies with longer exposure duration, however, this was not the case. In addition, the ovary weights were not affected in any study. If it would be assumed that an endocrine effect was responsible for the uterus weight changes, also the ovary weights would be assumed to be changed, however, this was not the case, also not in the study from [REDACTED] 1986a as shown in the following table:

Study	Ovary weight	Doses (ppm)			
		0	400	800	1200
[REDACTED] 1986a, M-146355-02-1 (SD)	absol (g)	0.0933±0.0015	0.0935±0.0230	0.0836±0.0100	0.0912±0.0186
	rel (%)	0.0353±0.0060	0.0351±0.0089	0.0314±0.0043	0.0358±0.0081

Thus, overall from the whole study package of apical studies, no evidence of an effect on the uterus or ovary weights was obvious.

### Prostate weight:

The DRAR, 2016 remarks that in a subchronic rat study ([REDACTED] 2002, M-211096-01-1) with doses of 0, 1000, 3000, 10000 and 20000 ppm, the prostate weights were reduced. The doses used in this dose range finding study were extremely high and caused very strong body weight reductions in all doses, but more severely from 3000 ppm on. The mentioned prostate weight reductions were clearly the consequence of this severe body weight effect and thus were only seen at such doses, i.e. from 3000 ppm on.

An overview of the prostate weights in this and in other studies is given in the following table:

### Subchronic studies

Study	Organ	Doses (ppm)							
		0	150	500	1000	1500	3000	10000	20000
Subchronic studies									
[REDACTED] 2002 M-211096-01-1 (Wistar rats)	Terminal body weight (g)	490.1			488.3		449.0	375.9***	343.2***
	Prostate weight absol (g)	0.676			0.526*		0.526*	0.376***	0.334***
	Prostate weight rel (%)	0.138			0.107		0.118	0.098**	0.099**
	Testes weight (g)	3.733			3.871		3.785	3.818	3.821
	Rel. Testes weight (%)	0.769			0.809		0.859	1.016***	1.121***
[REDACTED] 1986b, M-146380-02-1 (SD)	Prostate weight absol (g)	0.77	0.90	0.82		0.85			
	Prostate weight rel (%)	0.16	0.18	0.17		0.17			

\* p<0.05, \*\*p<0.01, \*\*\*p<0.001

It can be seen that the prostate weight reductions occurred at doses which also caused severe body weight reductions which is the main reason for this finding. If an endocrine effect would have been behind this finding also the testes weights should have been affected which was not the case since the absolute testes weights were not affected by treatment, with an increase of the relative weights as % of the body weight as an indirect arithmetical consequence of the severe body weight reductions.

Overall, these examples show that there is no evidence of an endocrine or hormonal influence on the discussed findings. If changes occurred they were not treatment-related but the consequence of variability in a wide variation range. We therefore conclude that the discussed tumor incidences were not affected by treatment or treatment-related hormonal effects.

An absence of a hormonal influence is furthermore supported by the results of ToxCast and Tox21 activity data for phenmedipham. The results from these systems did not show an agonistic or antagonistic effect on the androgen receptor neither an agonistic or antagonistic effect on the estrogen receptor.

Therefore, a hormonal induction of the tumor incidences by disturbed homeostasis of the hypothalamus-pituitary-gonad (thyroid) axis as stated in the CLH report is not supported by the aforementioned study data. As demonstrated, there is no evidence of an endocrine potential of phenmedipham. The overview of results in hormone sensitive organs (uterus, prostate, adrenals, testes and ovaries) shows that if changes occurred they were mostly not dose-related and/or secondary to body weight effects or toxicity so that a hormonal impact on such different organs from different sexes and thus different hormonal mechanisms appears rather implausible.

**Under point 10.11.4 Adverse effects on development, the CLH report states "We conclude that there is some evidence for developmental toxicity of phenmedipham and therefore classification for Category 2 is appropriate."**

We disagree with this conclusion:

**Discussion of 'runts'**

It is proposed to classify PMP based on an occurrence of runts in a rat developmental toxicity study (██████ 1988). In this study, doses of 0, 150, 450 or 1350 mg/kg body weight/day between days 6 and 15 post coitum were administered. This was associated with slightly reduced food consumption at 1350 mg/kg during the whole of the dosing period, minimally reduced food consumption at 150 and 450 mg/kg during the first five days of dosing and a slight dose-related retardation of body weight gain during the dosing period. There were no treatment-related effects on fetal parameters up to the highest dosage tested, 1350 mg/kg body weight/day. Effects on maternal parameters, although minimal, were observed down to the lowest dosage tested, 150 mg/kg bw, but there was no evidence of embryotoxicity or teratogenicity up to and including the highest dosage tested, 1350 mg/kg body weight/day. There was only one runt at 150 and 450 mg/kg bw each and two in the 1350 mg/kg bw group so that no dose response is obvious and thus no treatment effect. Based on the fetal and litter incidences no dose-relationship is obvious as shown in the following table:

Dose (mg/kg bw)	Litters	No. of fetuses	Runt - fetus number (sex)	Litter number	Fetal incidence (%)	Litter incidence (%)
0	24	293	-	-	-	-
150	23	250	331 (m)	33	0.40	4.35

450	21	241	430 (f)	68	0.41	4.76
1350	25	289	148 (f) 149 (f)	76 76	0.69	4.00

There was no dose-relationship, furthermore, it appeared to be associated with a lower average weights of the whole litter. The following table gives an overview of the litter weights of the litters with runts and their weights in comparison with the litter weights of the litters without runts:

Dose (mg/kg bw)	Litters	No. of fetuses	Runt - fetus no. (sex)	Litter number	Runt weight (g)	Average 'runt' litter weights (g) <sup>a</sup>	Other litter weights (g) <sup>b</sup>
0	24	293	-	-	-	-	4.6 (4.4-5.3)
150	23	250	331 (m)	33	2.5	4.2	4.6 (4.1-5.0)
450	21	241	430 (f)	68	2.2	4.2	4.7 (4.2-5.2)
1350	25	289	148 (f) 149 (f)	76 76	2.6 2.4	3.8	4.6 (3.8-5.1)

<sup>a</sup> average weights of litters with 'runts'

<sup>b</sup> average weights of males/females (range)

It can be seen that runts occurred as an isolated finding in litters which had lower litter weights compared to the other litters without runts which had litter weights comparable to the controls. Therefore, this was an artificial isolated phenomenon due to variability. Furthermore, the expression 'runt' is very subjective since it is often used for small pups when objective criteria were not found (██████████ 2003). However, this is not a malformation. As a definition often a fetus is defined 'runt' if the weight is half of the average litter weight. (ECETOC, monograph 31). If this is applied here, it can be seen from the table above that the weights of all fetuses called 'runts' were more than half of the average 'runt litter' weights. Therefore in this study per definition no 'runt' occurred so that this cannot be used to warrant classification. Also in the commenting phase UK denies an association with treatment, it states: "Regarding the developmental toxicity study by ██████████ (1988), the maternal toxicity appears to be more severe than 'very slight' as reported in B.6, since the corrected body-weight gain was reduced by 17% and 36% at 450 and 1350 mg/kg bw/d, respectively. Given this and the absence of a dose-response relationship (1, 1, 1 affected litters at 150, 450, 1350 mg/kg bw/d, respectively, with one small female in the control group), it seems unlikely that the occurrence of runts was a specific developmental effect of phenmedipham."

This finding was also not repeated in another rat study or in two rabbit studies that used equivalent or higher doses.

It was stated in the CLH report that PMP leads to a shift of the sex ratio in the ██████████, 1988 study.

The following table gives an overview of the % males and females in the ██████████, 1988 study (M-145693-01-1):

Sex ratio of fetuses	Dose (mg/kg bw)			
	0	150	450	1350
Males (%)	46.4	46.8	49.0	51.6
Females (%)	53.6	53.2	51.0	48.4

The table shows that a spuriously slightly higher percentage of males versus females was noted at the highest dose, however the percentages are close to the expected 50 % for both sexes so that this ratio does not appear to be abnormal, further it was not statistically significant. The main reason for this spurious change was the rather low % of males and respectively higher % of females in the control group which made the increase in % males and decrease in % females artificially looking higher. This was mainly due to variability.

That this was no treatment effect is confirmed by the pilot study which was performed in the same laboratory as a dose range finding study for the main study by ██████ 1988 (M-145777-01-1). The data of the pilot study are summarized in the following table:

Sex ratio of fetuses	Dose (mg/kg bw)	
	0	1000
Males (%)	46.3	40.7
Females (%)	53.7	59.3

The table shows that in this study no increase in % males was observed, just the opposite, the % of males was distinctly reduced and that of the females correspondingly increased although the highest dose was close to the one in the main study. This confirms that there was no increasing or decreasing effect on the percentages of the sexes, but that the observed changes are only due to a high variability.

In addition to this, also no effect on the sex ratios were seen in the other developmental toxicity study with phenmedipham in rats (██████ 1989 (M-146392-01-1)). The following table gives an overview of the sex ratio of the fetuses in this developmental toxicity study in rats:

Sex ratio of fetuses in rat developmental toxicity studies	Dose (mg/kg bw)			
	0	625	1250	2500
██████ et al, 1989 (M-146392-01-1)				
Males (%)	48.5	46.6	48.8	45.7
Females (%)	51.5	53.4	51.2	54.3

It is obvious that also this study does not confirm an increase in the ratio of males versus females since no increase in the percentage of male fetuses occurred in this study. Thus, the statement in the CLH report that the ratio of female fetuses was reduced and that this is evidence of an endocrine mechanism (██████ 1988) is not supported by the other studies with phenmedipham.

### Other reproduction aspects

It is concluded that there is no concern for either reproductive or developmental toxicity in the data provided. Although the multi-generation studies did not include all the parameters given as examples in the data requirements of possible effects on male and female reproductive impairment, we consider that an argument can be made that the information provided is sufficient to reach a conclusion. This should include information from the other available repeated-dose toxicity studies; for example, sperm parameters were measured in the 52 and 104 week rat studies (██████ 1998b) and no adverse effects were found. Furthermore, there were no effects on fertility indices in any of the multi-generation studies, and so it can be concluded that phenmedipham exposure did not adversely affect fertility in rats when tested at doses that were toxic to the dams.

**Under 10.13.3 the CLH report concludes that "Overall, in conclusion, based on haemotoxic effects seen in repeated dose toxicity studies in mice, rats and dogs, classification of phenmedipham for STOT-RE 2 ("H373: May cause damage to organs (blood) through prolonged or repeated oral exposure") is proposed. "**

We disagree with this conclusion. The major targets after phenmedipham treatment in rats are slight to moderate changes in red blood cell (RBC) parameters, leading to hemolytic anemia, increased activities of the liver and spleen - the organs mainly involved in the turnover of red blood cells - and compensatory medullar hematopoiesis. As another finding minimal to moderate methemoglobinemia was seen. For these effects in the conducted studies clear thresholds were determined. The most important studies for an assessment of hematological effects and the established NOAELs are discussed in this statement and the mechanism of hemosiderin formation and methemoglobinemia.

**Hemolytic anemia:**

Under normal conditions at the end of the lifetime of an erythrocyte (approximately 120 days) the erythrocytes are removed from the arterioles and get into the sinus of the spleen where old erythrocytes are destroyed. The erythrocyte fragments are then phagocytized by macrophages mainly in spleen, liver bone marrow and other organs. The iron released from hemoglobin is re-utilized whereas bilirubin and further heme catabolism products are excreted via bile, urine and feces. The released proteins transfer into the pool of amino acids which are also re-utilized. Anemia-causing compounds lead to a disturbance of this cycle after high doses. After a temporary higher hemolysis, like after a hemolytic anemia situation, this catabolism pathway can be temporarily overwhelmed so that an increased formation of iron-containing hemosiderin occurs which can lead to an increased deposition of hemosiderin in the reticulo-histiocytary system (RHS). Mainly spleen, but also liver and kidneys can be affected. Even larger amounts of hemosiderin deposits in tissues do not cause symptoms or impact organ functions. These findings are reversible once the erythrocyte turnover rate returns to the normal physiologic situation.

**Methemoglobinemia:**

Under normal physiological conditions methemoglobin occurs at approximately 1 % of the hemoglobin content. Methemoglobin, unlike hemoglobin, is not able to bind oxygen. The underlying mechanism is the oxidation of the Fe (II) in the hemoglobin molecule to Fe (III), either spontaneously or by chemicals with such an effect. The enzyme methemoglobin reductase reduces the Fe (III) to Fe (II) again to a normal situation. High doses of chemicals with a methemoglin-inducing effect can lead to higher methemoglobin formation which is reversible upon cessation of exposure to such a chemical.

**Evaluation of hematological effects in studies with phenmedipham****52-week rat study (██████████ 1987)**

Groups of 20 male and 20 female Sprague-Dawley rats were dosed with phenmedipham (98.5 %) via the diet at concentrations of 60 (low dose), 250 (middle dose) and 1000 ppm (high dose) for 52 weeks. Groups of 20 males and females each received untreated diet and acted as controls. The animals were ordered ca. 4 weeks old, weighing ca. 85 g (males) and 60 g (females). The animals were acclimatised for 15 days before treatment. Viability during the study was checked twice per day. All animals were examined for clinical signs daily, and all animals were palpated at least once a week. Each animal was weighed at weekly intervals starting from the week before the start of treatment until week 13 and thereafter at 4-weekly intervals. Food consumption was recorded once each week using the same schedule as with weighing the animals. Blood samples were taken from 10 males and 10 females per group for hematological and clinical chemistry investigations during weeks 13, 25 and 51 of dosing. The samples were taken from the same animals at the different time points. During weeks 25 and 51 of dosing, samples were taken also for urinalysis investigations from the same animals as those subjected to hematology sampling. After 52 weeks of dosing all animals were killed and autopsied. Histopathological examinations were initially carried out on all rats in the control and high dose groups and any premature decedents. Livers, kidneys and spleen of all animals were stained with Perls' Prussian Blue (PBR) and examined for hemosiderin deposition.

6 animal died, but not in a dose-related manner and, thus not due to treatment. As clinical signs scabby tail, encrustations around nose and eyes, alopecia, exophthalmia and immobile swollen limb joints were reported. They occurred with approximately equal incidence and severity in all groups during the study and were therefore not treatment-related. No statistically significant differences between the groups were noted in body weight gain or food consumption among either sex.

Hematologically, in the male and female high dose groups there were reductions in red cell parameters (hemoglobin (Hb), red blood cell count (RBC) and hematocrit (HCT)) at Weeks 13, 25 and 51. The intermediate dose group showed a reduction in HCT at all time points in the males and at Week 51 only in the females. Intermediate dose males also showed significant reductions in Hb levels at week 51. In high dose females Hb and HCT was decreased at all time points and RBC at weeks 13 and 51. At week 51 HCT was decreased in mid dose females also. During week 25 the low dose group females also showed reductions in Hb and HCT, but since the next higher dose of 250 ppm did not show an effect

and is comparable to the control value, this is regarded as due to variability and not to treatment. An overview of the hematological results during the different determination periods is given in the following tables:

Table 1: Hematological changes males – week 13

Group/Dose Level (ppm)	Phenmedipham	52 Week study Males		
		Hb	RBC	HCT
1 0	N	10	10	10
	Mean	15.5	7.87	0.440
	SD	0.6	0.17	0.016
2 60	N	9	9	9
	Mean	15.4	7.77	0.493
	SD	0.6	0.35	0.118
3 250	N	8	8	8
	Mean	15.0	7.78	0.418
	SD	0.5	0.53	0.018**
4 1000	N	10	10	10
	Mean	14.3	7.15	0.404
	SD	0.6***	0.40***	0.016***

\*\* : Significantly different from controls, P<0.01

\*\*\* : Significantly different from controls, P<0.001

N: Number of animals

Table 2: Hematological changes males – week 25

Group/Dose Level (ppm)	Phenmedipham	52 Week study Males		
		Hb	RBC	HCT
1 0	N	9	9	9
	Mean	15.2	7.82	0.413
	SD	0.7	0.36	0.016
2 60	N	10	10	10
	Mean	15.1	7.82	0.412
	SD	0.3	0.28	0.013
3 250	N	8	8	8
	Mean	14.6	7.54	0.389
	SD	0.9	0.35	0.023*
4 1000	N	10	10	10
	Mean	14.3	7.24	0.383
	SD	0.3**	0.26***	0.020**

\*\* : Significantly different from controls, P<0.01

\*\*\* : Significantly different from controls, P<0.001

N: Number of animals

Table 3: Hematological changes males – week 51

Group/Dose Level (ppm)	Phenmedipham	52 Week study Males		
		Hb	RBC	HCT
1 0	N	10	10	10
	Mean	15.3	8.18	0.432
	SD	0.6	0.36	0.016
2 60	N	10	10	10
	Mean	15.0	8.12	0.421
	SD	0.2	0.30	0.010
3 250	N	10	10	10
	Mean	14.6	7.93	0.404
	SD	0.6*	0.37	0.019***
4 1000	N	10	10	10
	Mean	14.1	7.42	0.392
	SD	0.3***	0.34***	0.015***

\* : Significantly different from controls, P<0.05

\*\*\* : Significantly different from controls, P<0.001

N: Number of animals

Table 4: Hematological changes females – week 13

Group/Dose Level (ppm)	Phenmedipham	52 Week study		Females
		Hb	RBC	HCT
1 0	N	10	10	10
	Mean	15.3	7.31	0.423
	SD	0.5	0.30	0.016
2 60	N	10	10	10
	Mean	15.4	7.60	0.432
	SD	0.4	0.17*	0.012
3 250	N	10	10	10
	Mean	15.0	7.34	0.416
	SD	0.5	0.33	0.018
4 1000	N	10	10	10
	Mean	14.5	6.81	0.402
	SD	0.8**	0.34***	0.022*

\*: Significantly different from controls, P<0.05

\*\* : Significantly different from controls, P<0.01

\*\*\*: Significantly different from controls, P<0.001

N: Number of animals

Table 5: Hematological changes females – week 25

Group/Dose Level (ppm)	Phenmedipham	52 Week study		Females
		Hb	RBC	HCT
1 0	N	10	10	10
	Mean	14.9	7.33	0.420
	SD	0.4	0.27	0.011
2 60	N	10	10	10
	Mean	14.0	7.08	0.397
	SD	0.9**	0.46	0-029*
3 250	N	10	10	10
	Mean	14.5	7.24	0.411
	SD	0.08	0.38	0.025
4 1000	N	9	9	9
	Mean	14.1	6.88	0.392
	SD	0.7*	0.38	0.021***

\*: Significantly different from controls, P<0.05

\*\* : Significantly different from controls, P<0.01

\*\*\*: Significantly different from controls, P<0.001

N: Number of animals

Table 6: Hematological changes females – week 51

Group/Dose Level (ppm)	Phenmedipham	52 Week study		Females
		Hb	RBC	HCT
1 0	N	9	9	9
	Mean	14.8	7.50	0.412
	SD	0.5	0.31	0.014
2 60	N	10	10	10
	Mean	14.6	7.66	0.409
	SD	0.4	0.24	0.012
3 250	N	10	10	10
	Mean	14.4	7.37	0.397
	SD	0.08	0.46	0.019*
4 1000	N	10	10	10
	Mean	13.7	6.96	0.378
	SD	0.4***	0.32**	0.015***

\*: Significantly different from controls, P<0.05

\*\* : Significantly different from controls, P<0.01

\*\*\*: Significantly different from controls, P<0.001

N: Number of animals

No effects on clinical chemistry which would be related to treatment were noted among males during

the experiment. Urinalysis did not show significant differences between the groups in pH, specific gravity and urinary volume among males throughout the whole study. A higher than expected incidence of positive blood pigment results in urine was noted among males, especially at 250 and 1000 ppm towards the end of the study. In several cases there was a corresponding presence of red blood cells in the microscopic examination. Significantly increased urinary volume was noted in mid and high dose animals at week 25, but not later. Specific gravity was correspondingly lowered in mid and high dose female groups at week 25. At the end of the experiment, several females were reported to have given positive blood pigment results.

Organ weight analyses showed an increase in spleen weights in males at 1000 ppm. In females a decrease in absolute kidney weights was noted at 1000 ppm. No gross pathology lesions attributed to treatment with phenmedipham were reported in the study report.

As described before, hemolytic anemia with secondary increase of hemoglobin turnover leads to an increased catabolism of hemoglobin to bilirubin and it is known that after a temporary higher hemolysis this catabolism pathway can be temporarily overwhelmed. In such a situation an increased formation of hemosiderin occurs which can lead to an increased deposition of hemosiderin in the reticulo-histiocytary system (RHS). Mainly spleen, but also liver and kidneys can be affected.

This was also seen in this study in which hemosiderin deposits were reported in some organs. High dose group males and females showed an increase in incidence and severity of Kupffer cell pigmentation in the liver, the pigment being haemosiderin (by PBR staining). The spuriously increased incidence of hemosiderin deposits in the low-dose (60 ppm) males is regarded as consequence of variability and not of treatment since the next higher dose of 250 ppm did not show a statistically significant effect and grade ++ incidence and overall incidence was lower again at this dose and without statistical significance. It can be seen that grade +/- and grade + incidences are not different from the control ones, only the grade ++ incidences are affected statistically significantly at the highest dose. The fact that no grade +++ findings occurred at any dose in males, only one at the high dose in females, speaks for a slight effect at the highest dose only, as seen by the increased incidences of grade ++ in males and females and of grade +++ incidences in females. Therefore, the overall incidences do not show a dose- and treatment-relationship in the dose range below 1000 ppm.

This is furthermore confirmed by the hemosiderin deposits in other organs which only had such findings at the highest dose of 1000 ppm. In the kidneys, only in high-dose males and females a slightly higher incidence and severity of proximal tubule cytoplasmic haemosiderin was seen. Also in the spleen which normally is the primary organ to be affected by consequences of hemolytic effects, only in the high dose males a slight increase of grade ++ hemosiderin deposit was seen, whereas grade +++ was even lower at the higher dose, and no effects of grade +/- or grade + in males and no effects in females were seen. As explained before, these findings are a consequence of the hemolytic effects only secondary to them, and thus can only occur at doses at which also hemolytic anemia effects, as a prerequisite, are seen. Therefore, the incidence for the 60 ppm males in the liver is not related to treatment since no hematological effects occurred at that dose. Since only an overwhelmed hemoglobin catabolism after a higher degree of hemolytic anemia can lead to an increased deposition of hemosiderin in the reticulo-histiocytary system (RHS), this can be expected only at doses which cause a more severe hemolytic anemia. Such an effect occurred only after higher doses of phenmedipham, but not at 60 ppm.

An overview of the aforementioned findings is given in table 7.

Table 7: Histopathology changes – week 52

Lesions	Incidence of lesions (numeric)							
	Treatment (ppm)							
	Males				Females			
	0	60	250	1000	0	60	250	1000
Liver:	20	20	20	20	20	20	20	20
Haemosiderin negative (P.B.R.)	6	1	2	0*	1	2	0	0
Haemosiderin positive (P.B.R.)								
(Grade +/-)	7	5	3	0**	14	12	4**	0***
(Grade +)	6	7	9	2	5	5	14*	10
(Grade ++)	1	7*	6	18***	0	1	2	9**
(Grade +++)	0	0	0	0	0	0	0	1
Kidneys:	20	20	20	20	20	20	20	20
Haemosiderin negative (P.B.R.)	5	4	2	0*	0	0	0	0
Haemosiderin positive (P.B.R.)								
(Grade +/-)	11	12	7	0***	5	5	3	1
(Grade +)	2	3	6	2	11	14	11	4*
(Grade ++)	2	1	5	8	4	1	6	11*
(Grade +++)	0	0	0	10***	0	0	0	4
Spleen:	20	20	20	20	20	20	20	20
Haemosiderin positive (P.B.R.)								
(Grade +/-)	0	2	0	0	0	0	0	0
(Grade +)	4	1	5	3	4	9	7	3
(Grade ++)	9	15	13	16*	13	10	12	12
(Grade +++)	7	2	2	1*	3	1	1	5

\* p<0.05, \*\*p<0.01, \*\*\*p<0.001

The described findings of hemosiderin deposition in the affected organs are sometimes reflected in the organ weights. In this study with phenmedipham only increases of the spleen weight at the highest dose in males were seen so that the hemosiderin deposition in the other organs apparently were so minimal that they were without an impact on the organ weights of liver and kidneys.

## Other rat studies

### Rat:

In order to compare the dose-response relationship regarding the hematological findings in the discussed 52-week study with other study results, a short overview of the hematological findings in other studies is given here.

The results of the comparison with the hematological findings in other relevant short- and long-term toxicology studies can be seen in the following two tables.

Table 8: Overview of the hematological results in short-term rat studies

Study	Doses	Main hematology and secondary effects	NOAEL methemoglobinemia	NOAEL RBC, Hb, MCG etc.	NOAEL hemosiderin deposition	Comment
13-week oral, dietary rat plus 4-week recovery (██████████, 1986b)	0-150-500-1500 ppm (m:9-18, 30-60, 90-181 mg/kg bw; f: 12-20, 38-64, 102-193 mg/kg bw)	RBC,Hb, MCH decreased: ≥500 ppm; increased hemosiderin deposition liver and kidney: ≥500 ppm (m,f) and in spleen (f)	na	150 ppm (9-18 (m)/ 12-20 (f) mg/kg bw)	150 ppm (9-18 (m)/ 12-20 (f) mg/kg bw)	Hematological effects were mainly reversible within the 4-week recovery period
13-week oral, dietary rat (██████████, 1986a)	0-400-800-1200 ppm (m: 30-60-92 mg/kg bw; f:33-72-122 mg/kg bw;	RBC, Hb, MCH decreased: ≥400 ppm (m: week 6) ≥400 ppm (f: week 6, 13) 1200 ppm (m: week (13); increased hemosiderin deposition liver and kidneys: ≥400 ppm (m,f) and in spleen (f)	na	<400 ppm (<30 (m)/<33 (f) mg/kg bw)	400 ppm (30 (m)/33 (f) mg/kg bw)	

13-week oral dietary rat (██████████ 1981)	0-50-500-5000 ppm (m: 3.5-35.4-366.5 mg/kg bw; f: 3.7-37.4-377.5 mg/kg bw)	RBC, Hb, MCH decreased: ≥500 ppm (m, f: increased hemosiderin deposition and hematopoiesis in spleen: 5000 ppm (m, f)	na	50 ppm (3.5 (m)/ 3.7 (f) mg/kg bw)	500 ppm (35.4 (m)/ 37.4 (f) mg/kg bw)	
--	--	---	----	------------------------------------	---------------------------------------	--

RBC= red blood cells Hb= hemoglobin, MCH=mean corpuscular hemoglobin, na= not applicable, m=males, f=females

Table 9: Overview of the hematological results in long-term rat studies

Overview of the hematological results in long-term rat studies						
Study	Doses	Main hematology and secondary effects	NOAEL methemoglobinemia	NOAEL RBC, Hb, MCG etc.	NOAEL hemosiderin deposition	Comment
52-week oral, dietary rat (██████████ 1988a)	0-60-250-1000 ppm (m: 3.4-14.6-58.7 mg/kg bw; f: 4.6-18.7-78.1 mg/kg bw)	RBC, Hb, MCH decreased: males: ≥250 ppm (m: week 13, 25, 51), f: 1000 ppm (week 13, 25,51) Increased hemosiderin deposition in liver and kidneys, m: 1000 ppm, f:≥250 ppm	na	60 ppm (3.4 (m) 250 ppm, (18.7 (f) mg/kg bw)	250 ppm (14.6 (m) mg/kg bw/60 ppm (4/6 (f) mg/kg bw)	
52-week oral, dietary rat (██████████ 1987)	0-60-250-1000 ppm (m: 4.2-17-70 mg/kg bw; f: 5.1-20-84 mg/kg bw)	RBC, Hb, MCH decreased: m: ≥250 ppm (m: week 13, f: week 13, 25); increased hemosiderin deposition in liver and kidneys: ≥250 ppm (m)	na	60 ppm (4.2 (m)/5.1 (f) mg/kg bw)	60 ppm (4.2 (m) mg/kg bw) /1000 ppm (84 (f) mg/kg bw)	
104-week dietary carcinogenicity rat study (██████████ 1988c)	0-60-250-1000 ppm (m/f: 2.1-7.3 (60), 8.9-30 (250), 33.1-114.3 mg/kg bw;	RBC, decreased: ≥250 ppm (f) ; 1000 ppm: increased pigment deposition in liver (m,f) and kidneys (m), increased hematopoiesis in sternum ( f not significant)	na	M: 1000 ppm (33.1-114.3 mg/kg bw); f: 60 ppm (2.1-7.3 mg/kg bw)	250 ppm (m/f: 8.9- 30.0 mg/kg bw)	Dose in mg/kg bw based on min.-max. of both sexes
104-week dietary carcinogenicity rat study (██████████ 1988b)	0-60-250-1000 ppm (m: 3.1-12.5-50.1 mg/kg bw; f: 4.1-16.8-67.5 mg/kg bw)	No hematology done; 1000 ppm: m/f: increased pigmented macrophages and Kupffer cells in livers	na	na	250 ppm (12.5 mg/kg bw (m)/ 16.8 mg/kg bw (f)	No DART report available
104-week chronic toxicity and carcinogenicity oral rat study (██████████ 2004)	0-100-500-2500 ppm (52 weeks: m: 5.6-27.1-137.0 mg/kg bw; f: 7.6-35.0-196.0 mg/kg bw; 104 weeks: m: 4.6-23.6-117.6 mg/kg bw; f: 6.4-33.1-170.5 mg/kg bw)	RBC, Hb, MCH decreased: ≥500 ppm; Met-Hb increased: m: ≥250 ppm (wk 13,26, f: 2500 ppm (≥wk 26); increased hemosiderin deposition liver and kidneys: ≥500 ppm (m,f) and in spleen (f)	100 ppm (4.6 (m) mg/kg bw/ 500 ppm (33.1 (f) mg/kg bw)	100 ppm (4.6 (m)/ 6.4 (f) mg/kg bw)	100 ppm (4.6 (m)/ 6.4 (f) mg/kg bw)	

RBC= red blood cells Hb= hemoglobin, MCH=mean corpuscular hemoglobin, na= not applicable, m=males, f=females

It can be seen that all other studies revealed a similar toxicological profile of phenmedipham. Also in the other studies, besides effects on body weight and food consumption, the main target of phenmedipham in rats were hematological effects, mainly on red blood cell parameters. These effects included reductions of the RBC counts, of Hb and MCH.

Hemosiderin deposition was generally observed in the liver and in the spleen, in some cases also in the kidneys in rats. Increased liver and spleen weights and in some cases also kidney weight changes were noted. A 13-week study with a 4-week recovery phase (██████████ 1986) showed that the changes in RBC parameters were almost completely reversible during the 4-week recovery period, as were also body weight changes and increases in hemosiderin deposition in liver and kidneys and partly spleen.

Occasionally, increased bilirubin concentrations were observed, also increased hemopoiesis in the bone marrow and increased reticulocyte counts in blood. The lowest NOAEL in all studies was at 50-60 -100 ppm, with ranges up to 500 ppm.

In a recent long-term study in rats (██████ 2004), which seems to be representative and important for this evaluation because of the much longer exposure time, three groups of 50 male and 50 female rats received phenmedipham orally, via the diet, at concentrations of 100, 500 or 2500 ppm (equivalent to doses of 4.6, 23.6 and 117.6 mg/kg bw/day for males and of 6.4, 33.1 and 170.5 mg/kg bw/day for females in the 104-week carcinogenicity phase, and of 5.6, 27.1 and 137.0 mg/kg bw/day for males and 7.6, 35.0 and 196.0 mg/kg bw/day for the females in the 52-week toxicity phase). A control group received untreated diet. A further 20 male and 20 female rats were allocated to each group. These animals comprised the toxicity phase of the study and were sacrificed after 52 weeks of treatment. In this study, hematologically, low hematocrit, haemoglobin concentration and red blood cell counts were seen in males and females at 2500 ppm, with a slight effect in 500-ppm males. At 2500 ppm, there was a consistent trend towards increased reticulocyte count and there were increased incidences and degree of anisocytosis in males receiving 2500 ppm and of hyperchromasia in males receiving 2500 ppm and during Week 13 in females receiving 500 ppm and in week 13 and 26 in those receiving 2500 ppm. Slight, but consistently higher methaemoglobin levels were recorded in females and at some time points also in males at 2500 ppm. At 500 ppm slightly high methaemoglobin levels were evident in week 13 and 26 in males. Spleen weights were increased in 2500-ppm males. Liver weights were slightly increased in females at 2500 ppm and kidney weights were slightly decreased in males and females at 2500 ppm. Histopathologically, in the liver a slightly increased incidence of pigmented macrophages or pigmented Kupffer cells in males and females at 2500 ppm was seen.

The incidences of pigment were given in the report for macrophages and Kupffer cells (which are also macrophages) separately, they can be seen in the following tables.

Table 10: 104-week rat study: liver changes, week 52

Group/sex		1M	2M	3M	4M	1F	2F	3F	4F
Level (ppm)		0	100	500	2500	0	100	500	2500
Pigmented macrophages	Minimal	0	0	0	3	3	5	2	10
	Moderate	0	0	0	0	0	0	1	0
	Total	0	0	0	3	3	5	3	10 a
Pigment in Kupffer cells	Minimal	0	0	1	5	0	0	0	4
	Total	0	0	1	5 a	0	0	0	4 a
n		20	20	20	20	20	20	19	19

Significant when compared with group 1: a- p< 0.05

n = number of animals examined

Table 11: 104-week rat study: liver changes, week 104

Group/sex		1M	2M	3M	4M	1F	2F	3F	4F
Level (ppm)		0	100	500	2500	0	100	500	2500
Pigmented macrophages	Minimal	2	1	3	18	8	8	14	20
	Slight	0	0	0	2	0	2	3	4
	Moderate	1	0	0	1	0	0	0	0
	Total	3	1	3	21 b	8	10	17	24 b
Pigment in Kupffer cells	Minimal	0	1	2	16	2	1	2	17
	Slight	0	0	0	5	0	0	0	4
	Total	0	1	2	21 b	2	1	2	21 b
n		50	50	50	50	50	50	50	49

Significant when compared with group 1: a- p< 0.05

n = number of animals examined

The tabular overviews clearly show that there were effects at the highest dose of 2500 ppm, but not at lower doses which also confirms that the spurious liver finding in 60 ppm males in the discussed 52-week rat study is not treatment-related.

In the spleen a high incidence of congestion was seen in all male treated groups and in females at 500 or 2500 ppm with slightly increased incidences of haemosiderosis or extramedullary haemopoiesis in males and females at 2500 ppm.

Thus, the NOAEL for all effects, including hematology effects, was established at 100 ppm. Like the

other studies mentioned before, also this long-term study confirms clearly the NOAEL of 60 ppm in the 52-week study as a NOAEL for the hematological effects of phenmedipham.

### **Studies in other species:**

An 8-week study in mice with oral administration revealed the same type of effects as seen in the rat studies. Again slight anemia was noted together with increased liver weight, and hemosiderin deposition in the liver. Also increased methemoglobin levels were observed, The highest observed methemoglobin values were 4.0 – 4.5 % at approximately 2000 mg/kg bw/day in mice (compared to 2.3 % in controls) and an increase in hepatic extramedullary hematopoiesis. The NOAEL in mice is 125 mg/kg bw/day and, thus, much higher than in the rat.

Furthermore, these methemoglobin levels are approximately in the range of the level of 4% which is regarded as maximum non-adverse level (██████████ 2005, Food and Chemical Toxicology 43 (2005) 1569-1593).

Also in the dog decreases in red blood cell parameters were seen together with extramedullary hematopoiesis, again indicating slight anemia. Transient hematological changes were also observed in the 2-year dog study, but at rather high doses only, e.g. the NOAEL in the 2-year dog study is higher than 28 mg/kg bw/day. Thus, in summary, the toxicological profile in these species were similar to the one in rats. Mostly moderate and reversible (within 4 weeks) hematological changes in red blood cell parameters, liver and spleen weight changes (sometimes also kidneys), hemosiderin deposition in spleen, liver and kidneys, and increased medullar and/or extramedullar hematopoiesis were seen, with very high NOAELs. Also a slight increase in methemoglobin levels (up to 4%) was noted, but adverse or non-reversible health effects as a result of the slight methemoglobinemia could not be identified.

### **Overall conclusion on the hematological findings after phenmedipham**

The most important outcome of this analysis is that all rat studies and studies in other species show that the hematological effects were not so severe that they could be regarded as findings of ‘significant’ or ‘severe’ toxicity. Also the methemoglobin levels were in ranges which cannot be defined as adverse. The findings have a NOAEL of 60 ppm or even higher than 60 ppm. In the other studies mostly NOAELs were 100 ppm, ranging up to 500 ppm. A recent 104-week chronic toxicity and carcinogenicity study with a thorough evaluation of all relevant hematological parameters over many timepoints of the long-term study confirmed a NOAEL of 100 ppm for all hematological parameters, including hemosiderin formation and deposition.

**Appendix 1**

**Weight of Evidence Analysis on the Genotoxicity of Phenmedipham**

**Prepared By:**

**[REDACTED], Ph.D.**

**Exponent, Inc.**

**[REDACTED]**

**[REDACTED]**

**U.S.A.**

**Date**

**12 April 2018**

## Weight of Evidence Analysis on the Genotoxicity of Phenmedipham

### Introduction:

The genotoxicity data on the pesticide active ingredient phenmedipham (3-methoxycarbonylamino-phenyl 3-methylcarbanilate) was evaluated by EFSA as part of their risk assessment (██████ et al., 2017). This review expressed a critical concern because a genotoxic potential for phenmedipham could not be excluded. This concern resulted because of the following: a) positive results in the *in vitro* chromosomal aberration assays, and b) bone marrow was not sufficiently exposed in the follow-up *in vivo* mouse micronucleus test.

The present document examines the above issues in the context of all the available data on phenmedipham and the guidance(s) from EFSA relating to the bone marrow exposure (Hardy et al., 2017).

### Genotoxicity data on phenmedipham (see Table 1):

Phenmedipham was evaluated for bacterial mutagenicity in seven studies and the results were consistently negative. In three independent studies, no evidence for mutagenic activity was detected in mammalian cell cultures. There was also no evidence for DNA damage/repair when rat primary hepatocytes were exposed to phenmedipham in culture.

In the *in vitro* chromosomal aberration assay, phenmedipham was clastogenic (mostly at cytotoxic doses) in three independent studies. However, there was no evidence for clastogenic or aneugenic activity *in vivo* for this substance. Phenmedipham was negative in four studies that evaluated clastogenic /aneugenic potential using the mouse bone marrow micronucleus induction. In addition, phenmedipham did not induce chromosomal aberrations in mouse spermatogonial cells.

Thus, the totality of genotoxicity data suggests that phenmedipham is not likely to be genotoxic *in vivo* and the positive response in the *in vitro* chromosomal aberration assay is rather an exceptional finding. While the available data do not permit the elucidation of the mode-of-action (MoA) responsible for the *in vitro* clastogenic activity, it is reasonable to infer that the observed response might be secondary to cytotoxicity and/or other perturbations in the cellular homeostasis at the high doses normally employed in these *in vitro* studies. The endpoints used *in vitro* to determine cytotoxicity do not always cover the entire spectrum of cytotoxic events and hence it is often difficult to conclusively rule in or rule out a role for cytotoxicity for the observed *in vitro* response.

The absence of genotoxic activity in the mouse bone marrow micronucleus tests rules out the relevance of the *in vitro* MoA for *in vivo* situations. However, EFSA was concerned that the bone marrow was not sufficiently exposed to the test substance in the *in vivo* micronucleus test and hence a genotoxic potential for phenmedipham could not be excluded. This issue of bone marrow exposure is examined below using the various lines of evidence prescribed in the guidance from the agency on this topic (Hardy et al., 2017 in 'Clarification of some aspects related to genotoxicity assessment; EFSA Journal 2017;15(12):5113):

1. Toxicity to the bone marrow in the micronucleus test: The guidance states that a decrease in the ratio of polychromatic to normochromatic erythrocytes is sufficient evidence of bone marrow exposure. In one of the micronucleus studies (██████, 1985), phenmedipham was tested at an oral gavage dose of 15,000 mg/kg bw (>7X the currently recommended limit dose). This dose caused a reduced polychromatic erythrocyte count (PCE) which, according to the study director, was evidence that the dose affected erythropoiesis. There was no effect of treatment on micronucleus induction in this study. These data support the line of evidence that the bone marrow was exposed sufficiently at this high dose level in the micronucleus test.
2. Test substance detected systemically and in the bone marrow in toxicokinetic studies: In an ADME study (██████, 1994), mean plasma levels of methylphenyl-labelled phenmedipham, which were measured 96 hours after administration of a single dose of 1000 mg/kg bw, were 23.6 and 41.0 µg/g in males and females, respectively. Maximum individual levels of up to 68.9 µg/g were reached in females. In bone marrow, mean levels of 1.65 and 2.24 µg/g were measured in males and females, respectively, with maximum individual levels of up to 4.8 µg/g in females. In addition, bone marrow exposure was demonstrated in a mouse quantitative whole body autoradiography study (██████ 2017). Thus, the available data provide evidence for the presence of the test substance systemically and in the bone marrow.
3. Systemic toxicity observed in repeat dose studies: The EFSA risk assessment document (██████ et al., 2017) states that “[i]n all short-term studies in rats, mice and dogs, the critical effects observed were related to haemolytic anaemia (increased methaemoglobin (MetHB), decrease in haemoglobin, haematocrit and red blood cells, increased extramedullary haematopoiesis and hemosiderin deposition in spleen, liver and kidneys).” These effects are clear indications of systemic toxicity. Specifically, a subacute study treated male and female mice with concentrations of 0, 1000, 5000 and 15000 ppm via the diet over a period of 8 weeks. These concentrations are equivalent to doses of 125.3, 623.4 and 1926.8 mg/kg bw/day in males and of 143.6, 698.9 and 2070.8 mg/kg bw in females. Reductions of red blood cell count (RBC), hemoglobin (Hb) and packed cell volume (PCV) were seen dose-dependently at all doses in males (≥ 125.3 mg/kg bw) and beginning at 5000 ppm (≥ 698.9 mg/kg bw) in females. Increased levels of methemoglobin were observed dose-dependently from doses of 623.4 and 698.9 mg/kg bw/day on in males and females, respectively. Thus, data from repeat dose toxicity studies provide support the systemic availability of phenmedipham following oral administration.
4. Test substance detected systemically in specified blood/plasma samples in a micronucleus study: A new *in vivo* micronucleus test performed according to the current guideline OECD 474 used oral doses of 0, 500, 1000, and 2000 mg/kg bw. Separate experiments were also conducted to demonstrate exposure of bone marrow. The bioanalysis showed that plasma samples of the animals treated with the high dose contained quantifiable amounts of the test substance. These data support systemic availability of and bone marrow exposure to phenmedipham.

## **Conclusion**

Collectively, the above lines of evidence clearly indicate that bone marrow was exposed to the test substance in the mouse micronucleus tests on phenmedipham. Since phenmedipham was tested up to a dose level of 15,000 mg/kg bw (more than 7X the limit dose for these studies), it is reasonable to conclude that the substance was tested at high enough doses to result in sufficient exposure of bone marrow. The available data to support bone marrow exposure in phenmedipham micronucleus studies are rather exemplary and one may argue that any further *in vivo* work is unlikely to augment this already rich data set supporting no concern for genotoxicity. However, the applicant is open to discussions on possible additional approaches, including experimental ones, to help remove any concern regarding the genotoxic potential of phenmedipham.

Table 1: Overview of Genetic Toxicity Studies on Phenmedipham

Test system	Metabolizing system	Result	Reference
<b>In vitro</b>			
<i>Salmonella typhimurium</i> Reverse mutation assay	+S9 mix, rat liver	Negative	██████████, 1987/M-145673-01-1
	-S9 mix	Negative	
<i>Salmonella typhimurium</i> Reverse mutation assay	+S9 mix, rat liver	Negative	██████████, 1990
	-S9 mix	Negative	
<i>Salmonella typhimurium</i> Reverse mutation assay OECD TG 471	+S9 mix, rat liver	Negative	██████████, 2014
	-S9 mix	Negative	New
<i>Salmonella typhimurium</i> Reverse mutation assay	+S9 mix, rat liver	Negative	██████████, 1995
	-S9 mix	Negative	
<i>Salmonella typhimurium</i> Reverse mutation assay			██████████ <i>et al.</i> , 1976
	-S9 mix (spot test)	Negative	
<i>Escherichia coli</i> Reverse mutation assay			██████████ <i>et al.</i> , 1976
	-S9 mix (spot test)	Negative	
Rec-assay in <i>Bacillus subtilis</i>			S██████████ <i>et al.</i> , 1976
	-S9 mix (spot test)	Negative	
Chromosome aberration assay in human lymphocytes	+S9 mix, rat liver	Positive at cytotoxic dose levels	██████████, 1994/ M-145797-01-1
	-S9 mix	Positive at cytotoxic dose levels	
Chromosome aberration assay in Chinese hamster ovary cells	+S9 mix, rat liver	Positive at cytotoxic dose levels	██████████, 1986/ M-146379-01-1
	-S9 mix	Positive at cytotoxic dose levels	
Chromosome aberration assay in Chinese hamster ovary cells	+S9 mix, rat liver	Negative	██████████, 1991
	-S9 mix	Negative	
Chromosome aberration assay in human lymphocytes	+S9 mix, rat liver	Negative	██████████, 2016 / M-122350-01-1
	-S9 mix	Positive	New
HGPRT locus mutation test in Chinese hamster V79 cells	+S9 mix, rat liver	Negative	██████████, 1987/ M-145664-01-1
	-S9 mix	Negative	
HGPRT locus mutation test in mouse lymphoma L5187Y cells	+S9 mix, rat liver	Negative (isolated outlier which could not be reproduced)	██████████, 1986/ M-146378-01-1
HGPRT locus mutation test in Chinese hamster V79 cells	+S9 mix, rat liver	Negative	██████████, 2016/ M-587893-01-1
	-S9 mix	negative	New
Unscheduled DNA synthesis for DNA damage in primary rat hepatocytes	Exogenous metabolic activation not applied	Negative	██████████, 1988/ M-145675-01-1
<b>In vivo</b>			
Bone marrow cell micronucleus test in NMRI mice	Not applicable	Negative	██████████ 1985/ M-146384-01-1
Bone marrow cell micronucleus test in NMRI mice	Not applicable	Negative	██████████ 1978/ M-145580-01-2
Chromosome aberration assay in NMRI mouse spermatogonial cells	Not applicable	Negative	██████████ 1987/ M-146385-01-1
Bone marrow cell micronucleus test in NMRI mice (500, 1000, and 2000 mg/kg b.w. p.o. by gavage)	Not applicable	Negative	██████████, 2017/ M-591798-01-1
Chromosome aberration assay in NMRI mouse spermatogonial cells	Not applicable	Negative	██████████ 1987/ M-146385-01-1
Bone marrow cell micronucleus test in NMRI mice (500, 1000, and 2000 mg/kg b.w. p.o. by gavage)	Not applicable	Negative	██████████ 2017/ M-591798-01-1
			New